Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care.
In June 2020, I was seeing consults in the damp, windowless basement of a community hospital in North Carolina.
Richard Bleicher, a professor in the Department of Surgical Oncology and clinical director of the Breast Service Line, has been promoted to chief of the new Division of Breast Surgery at Fox Chase Cancer Center.
LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.
University of Pittsburgh and UPMC Hillman Cancer Center researchers have developed a novel prompt, or ‘nudge,’ embedded in the electronic health record that flags, for treating surgeons, older patients with early-stage breast cancer who may be at risk for unnecessary lymph node surgery.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.
Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.
